Pembrolizumab versus Ipilimumab in Advanced Melanoma
2015 · New England Journal of Medicine · 5,734 citations
https://doi.org/10.1056/nejmoa1503093
M
Michal Lotem
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
197
Papers
18.5K
Citations
40
h-index
87
i10-index
Michal Lotem is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Immunotherapy and Immune Responses & CAR-T cell therapy research. The author has an h-index of 40, co-authored 168 publications.
ORCID: 0000-0003-1703-8008Papers by this author
worksPembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
2017 · The Lancet · 1,214 citations
https://doi.org/10.1016/s0140-6736(17)31601-x
Predictors of responses to immune checkpoint blockade in advanced melanoma
2017 · Nature Communications · 200 citations
https://doi.org/10.1038/s41467-017-00608-2
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
2020 · Nature Communications · 153 citations
https://doi.org/10.1038/s41467-020-14639-9
Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma
2004 · British Journal of Cancer · 28 citations
https://doi.org/10.1038/sj.bjc.6601563
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
2019 · Journal of Translational Medicine · 18 citations
https://doi.org/10.1186/s12967-019-2081-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat